A Phase 3 interventional study of Aripiprazole IM Depot and Placebo in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 49 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-02-16.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 29th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2012, is one of 34 in phase 3, and was the 74th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 340 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 30th largest by enrollment of the 111 interventional ones that give a count, is one of 5 that started in 2012, is one of 50 in phase 3, and was the 49th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the overall efficacy of aripiprazole intramuscular (IM) depot as acute treatment in subjects with schizophrenia.
The secondary purpose is to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for 12 weeks to adult subjects with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting BOTH of the following at screening and baseline:
Specific psychotic symptoms on the PANSS as measured by a score of > 4 on each of the following items (possible scores of 1 to 7 for each item)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks
Drug: Aripiprazole IM Depot
Matching placebo
Drug: Placebo
Also known as: OPC-14597, Lu AF41155
Matching Placebo
Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score.
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 that indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The PANSS total score was the sum of the rating scores for 7 positive subscale items, 7 negative subscale items, and 16 general psychopathology subscale items from the PANSS panel. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome). The primary statistical comparison was performed using the Mixed Model Repeated Measure (MMRM) approach.
Time frame: Baseline to Week 10
Mean Change From Baseline to Endpoint in Clinical Global Impression-Severity Scale (CGI-S) Score.
The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.
Time frame: Baseline to Week 10
Mean Change From Baseline to Endpoint in PANSS Positive Subscale Score.
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline to Week 10
Mean Change From Baseline to Endpoint in PANSS Negative Subscale Score.
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline to Week 10
Mean Change From Baseline to Endpoint in Personal and Social Performance Scale (PSP) Score.
The PSP was a validated clinician scale that measured personal and social functionining in 4 domains: socially useful activities eg, work and study), personal and social relationships, self-care, disturbing and aggressive behaviours. Impairement in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval and the study physician's judgement to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
Time frame: Week 10
Mean Clinical Global Impression-Improvement Scale (CGI-I) Score at Endpoint.
The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.
Time frame: Week 10
Responder Rate Based on PANSS Total Score.
Responder rate was defined as ≥30% reduction from Baseline in PANSS Total Score. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Week 10
The trial was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of aripiprazole IM (intramuscular) depot as treatment for an acute episode of schizophrenia in adult participants. The trial was conducted in 55 sites.
| Milestone | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Started | 168 | 172 |
| Completed | 94 | 65 |
| Not completed | 74 | 107 |
| Withdrew: Lost to follow-up | 9 | 10 |
| Withdrew: Adverse event | 7 | 13 |
| Withdrew: Met withdrawal criteria | 7 | 6 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 35 | 17 |
| Withdrew: Lack of efficacy | 15 | 60 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 that indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The PANSS total score was the sum of the rating scores for 7 positive subscale items, 7 negative subscale items, and 16 general psychopathology subscale items from the PANSS panel. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome). The primary statistical comparison was performed using the Mixed Model Repeated Measure (MMRM) approach.
| Units on a scale | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Week 1 (N= 162, 167) | -8.9 ± 0.9 | -5.0 ± 0.9 |
| Week 2 (N= 144, 157) | -15.2 ± 1.2 | -8.3 ± 1.2 |
| Week 4 (N= 134, 140) | -19.0 ± 1.4 | -9.8 ± 1.3 |
| Week 6 (N= 126, 117) | -21.5 ± 1.5 | -10.3 ± 1.5 |
| Week 8 (N= 108, 96) | -23.7 ± 1.6 | -9.7 ± 1.6 |
| Week 10 (N= 99, 81) | -26.8 ± 1.6 | -11.7 ± 1.6 |
The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.
| Units on a scale | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Week 1 (N= 162, 168) | -0.4 ± 0.1 | -0.2 ± 0.1 |
| Week 2 (N= 144, 157) | -0.8 ± 0.1 | -0.4 ± 0.1 |
| Week 4 (N= 134, 140) | -1.0 ± 0.1 | -0.4 ± 0.1 |
| Week 6 (N= 126, 117) | -1.2 ± 0.1 | -0.5 ± 0.1 |
| Week 8 (N= 108, 96) | -1.3 ± 0.1 | -0.6 ± 0.1 |
| Week 10 (N= 99, 81) | -1.4 ± 0.1 | -0.6 ± 0.1 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Week 1 (N= 162, 167) | -3.5 ± 0.3 | -2.1 ± 0.3 |
| Week 2 (N= 144, 157) | -5.7 ± 0.4 | -3.4 ± 0.4 |
| Week 4 (N= 134, 140) | -7.0 ± 0.5 | -3.9 ± 0.4 |
| Week 6 (N= 126, 117) | -8.2 ± 0.5 | -4.4 ± 0.5 |
| Week 8 (N= 108, 96) | -8.9 ± 0.5 | -4.1 ± 0.5 |
| Week 10 (N= 99, 81) | -10.0 ± 0.5 | -4.9 ± 0.5 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Week 1 (N= 162, 167) | -1.6 ± 0.2 | -0.7 ± 0.2 |
| Week 2 (N= 144, 157) | -2.4 ± 0.3 | -1.2 ± 0.3 |
| Week 4 (N= 134, 140) | -3.1 ± 0.4 | -1.3 ± 0.4 |
| Week 6 (N= 126, 117) | -3.5 ± 0.4 | -1.3 ± 0.4 |
| Week 8 (N= 108, 96) | -4.0 ± 0.4 | -1.4 ± 0.4 |
| Week 10 (N= 99, 81) | -4.5 ± 0.5 | -1.6 ± 0.5 |
The PSP was a validated clinician scale that measured personal and social functionining in 4 domains: socially useful activities eg, work and study), personal and social relationships, self-care, disturbing and aggressive behaviours. Impairement in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval and the study physician's judgement to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
| Units on a scale | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Mean Change From Baseline to Endpoint in Personal and Social Performance Scale (PSP) Score. | 12.3 ± 1.2 | 5.2 ± 1.2 |
The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.
| Units on a scale | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Mean Clinical Global Impression-Improvement Scale (CGI-I) Score at Endpoint. | 2.7 ± 1.2 | 3.7 ± 1.3 |
Responder rate was defined as ≥30% reduction from Baseline in PANSS Total Score. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| participants | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Responder Rate Based on PANSS Total Score. | 60 | 24 |
Collected over Adverse events were monitored from ICF signed untill Follow-up 14 (± 2) days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole IM Depot 400/300mg | — | 8/167 (4.8%) | 91/167 (54.5%) |
| Placebo | — | 6/172 (3.5%) | 68/172 (39.5%) |
| Event | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| SchizophreniaPsychiatric disorders | 3/167 | 3/172 |
| Psychotic disorderPsychiatric disorders | 2/167 | 2/172 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/167 | 0/172 |
| AgitationPsychiatric disorders | 1/167 | 0/172 |
| Substance abusePsychiatric disorders | 1/167 | 0/172 |
| Suicidal ideationPsychiatric disorders | 1/167 | 0/172 |
| HypotensionVascular disorders | 0/167 | 1/172 |
| Event | Aripiprazole IM Depot 400/300mg | Placebo |
|---|---|---|
| Weight increasedInvestigations | 28/167 | 12/172 |
| HeadacheNervous system disorders | 24/167 | 28/172 |
| AkathisiaNervous system disorders | 19/167 | 6/172 |
| ConstipationGastrointestinal disorders | 16/167 | 12/172 |
| DyspepsiaGastrointestinal disorders | 10/167 | 11/172 |
| AgitationPsychiatric disorders | 9/167 | 11/172 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/167 | 10/172 |
| ToothacheGastrointestinal disorders | 9/167 | 8/172 |
| Injection site painGeneral disorders | 9/167 | 1/172 |
| SedationNervous system disorders | 9/167 | 2/172 |
| Age, Continuous(Years) | Aripiprazole IM Depot 400/300mg | Placebo | Total |
|---|---|---|---|
| Mean | 42.1 ± 11.0 | 42.7 ± 10.9 | 42.4 ± 11.0 |
| Sex: Female, Male(Participants) | Aripiprazole IM Depot 400/300mg | Placebo | Total |
|---|---|---|---|
| Female | 38 | 33 | 71 |
| Male | 130 | 139 | 269 |
The record gives a start of Oct 2012, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 6 months after primary completion. A results delay was requested in Oct 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →